There are currently 126 clinical trials in Gilbert, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Banner MD Anderson Cancer Center, Mercy Gilbert Medical Center, GSK Investigational Site and Banner MD Anderson Cancer Center ( Site 0028). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT02912312
Recruiting
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: MD Anderson Cancer Center (Banner), Gilbert, Arizona
Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates
Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women
NCT05169840
Recruiting
The investigators propose to genotype males and females at age 40 years and older, who are asymptomatic and without known heart disease (N=2000). DNA from a blood sample will be genotyped for millions of genetic risk variants for CAD by Baylor College of Medicine Human Genome Sequencing Center Clinical Laboratory (HGSC-CL) in a CLIA-approved laboratory. The overall objective after 2 years is to determine if genetic screening for risk of CAD in asymptomatic men and women has the discriminatory p... Read More
Gender:
All
Ages:
Between 40 years and 60 years
Trial Updated:
11/22/2023
Locations: Mercy Gilbert Medical Center, Gilbert, Arizona
Conditions: Coronary Artery Disease, Genetic Predisposition to Disease
Register for Updates
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
FX Shoulder Solutions Retrospective / Prospective Clinical Study
NCT06077942
Recruiting
Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions.
Gender:
All
Ages:
All
Trial Updated:
10/10/2023
Locations: OrthoArizona, Gilbert, Arizona
Conditions: Rotator Cuff Syndrome of Shoulder and Allied Disorders, Osteoarthritis Shoulder, Fracture, Shoulder
Register for Updates
FX Shoulder Prospective Clinical Study
NCT06078865
Recruiting
Prospective Multi-Center Registry on study subjects with implanted devices marketed and legally commercialized in the USA by FX Shoulder Solutions.
Gender:
All
Ages:
All
Trial Updated:
10/05/2023
Locations: OrthoArizona, Gilbert, Arizona
Conditions: Osteoarthritis Shoulder, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Fracture, Shoulder
Register for Updates
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
NCT03747458
Recruiting
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjec... Read More
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/22/2023
Locations: Arizona Allergy and Immunology Research, Gilbert, Arizona +1 locations
Conditions: Bilateral Nasal Polyposis
Register for Updates
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT04370587
Recruiting
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Melanoma, Solid Tumor, NSCLC, HNSCC, Sarcoma, Squamous Cell Carcinoma
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756
Recruiting
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Register for Updates
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
NCT05266612
Recruiting
This is a Phase 1, open-label, dose-escalation trial using standard 3+3 dose-escalation design in patients with advanced malignant solid tumors. All patients within a given dose level cohort will be treated with the same dose schedule of VG2025, administered as bi-weekly intratumoral injections at Day 1 and Day 15. Dose limiting toxicity (DLT) evaluation period is for 4 weeks from the start of treatment, Day 1, through Day 28. There are two parts to this study a monotherapy arm and a combinatio... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/10/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Solid Tumor
Register for Updates